G1T38: Experimental Treatment for Estrogen Receptor-Positive, HER2-Negative (ER+, HER2-) Breast Cancer

Scientific rationale and therapeutic potential

G1T38 is a potent and selective oral CDK4/6 inhibitor designed to block the proliferation of breast-cancer cells and induce tumor-cell death when combined with a selective estrogen receptor degrader (SERD), such as Faslodex®. G1T38 has the potential to be best-in-class versus other oral CDK4/6 inhibitors.

Preclinical and clinical results (see: Publications)

- published preclinical data demonstrating G1T38 is more potent and has less toxicity than other oral CDK4/6 inhibitors in development;
- Phase 1 trial in 75 healthy volunteers demonstrated G1T38 was well tolerated with no grade 3/4 adverse events and no serious adverse events.

G1 is recruiting patients for a Phase 1b/2a trial in ER+, HER2- breast cancer

G1T38-02 Study

- ER+, HER2- breast cancer, after endocrine therapy failure
- multi-center, randomized, open-label
- G1T38 + Faslodex®
- approximately 80 patients
- ClinicalTrials.gov identifier: NCT02983071

79 T.W. Alexander Drive | 4501 Research Commons, Suite 100 | Research Triangle Park, NC 27709
www.g1therapeutics.com | contact: clinicalinfo@g1therapeutics.com | www.g1cancertrials.com